- Home
- SNTG vs RDHL Comparison
SNTG vs RDHL Comparison
Compare SNTG & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTG
- RDHL
- Stock Information
- Founded
- SNTG 2009
- RDHL 2009
- Country
- SNTG China
- RDHL Israel
- Employees
- SNTG N/A
- RDHL N/A
- Industry
- SNTG Finance: Consumer Services
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- SNTG Finance
- RDHL Health Care
- Exchange
- SNTG Nasdaq
- RDHL Nasdaq
- Market Cap
- SNTG 5.9M
- RDHL 6.8M
- IPO Year
- SNTG 2021
- RDHL N/A
- Fundamental
- Price
- SNTG $1.87
- RDHL $4.76
- Analyst Decision
- SNTG
- RDHL
- Analyst Count
- SNTG 0
- RDHL 0
- Target Price
- SNTG N/A
- RDHL N/A
- AVG Volume (30 Days)
- SNTG 430.5K
- RDHL 9.0K
- Earning Date
- SNTG 12-17-2024
- RDHL 04-07-2025
- Dividend Yield
- SNTG N/A
- RDHL N/A
- EPS Growth
- SNTG N/A
- RDHL N/A
- EPS
- SNTG N/A
- RDHL N/A
- Revenue
- SNTG $146,472.00
- RDHL $3,707,000.00
- Revenue This Year
- SNTG N/A
- RDHL $224.90
- Revenue Next Year
- SNTG N/A
- RDHL $82.69
- P/E Ratio
- SNTG N/A
- RDHL N/A
- Revenue Growth
- SNTG N/A
- RDHL N/A
- 52 Week Low
- SNTG $1.65
- RDHL $4.76
- 52 Week High
- SNTG $3.97
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- SNTG 49.72
- RDHL 26.11
- Support Level
- SNTG $1.71
- RDHL $5.20
- Resistance Level
- SNTG $1.96
- RDHL $5.50
- Average True Range (ATR)
- SNTG 0.10
- RDHL 0.23
- MACD
- SNTG -0.00
- RDHL -0.07
- Stochastic Oscillator
- SNTG 62.50
- RDHL 0.00
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.